ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
151 | (±¹¿Ü)SCI | Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017 |
150 | (±¹¿Ü)SCI | Prolonged Use of Carnitine-Orotate Complex (Godex¢ç) Is Associated with Improved Mortality: A Nationwide Cohort Study |
149 | (±¹¿Ü)SCI | FGM-Based Remote Intervention for Adults With Type 1 Diabetes: The FRIEND Randomized Clinical Trial |
148 | (±¹¿Ü)SCI | Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels |
147 | (±¹¿Ü)SCI | Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: A randomized controlled trial |
146 | (±¹¿Ü)SCI | The Risk of Neurodegenerative Diseases in Patients With Acromegaly: A Cohort Study |
145 | (±¹³»)KCI | Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents |
144 | (±¹¿Ü)SCIE | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study. |
143 | (±¹¿Ü)SCI | Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-calculate Marker for All-cause and Cardiovascular Mortality |
142 | (±¹³»)SCIE | Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study |
Copyright ¨Ï chamc, All rights reserved.